SEK 1005

Drug Profile

SEK 1005

Latest Information Update: 07 Jan 2004

Price : $50

At a glance

  • Originator Sekisui
  • Class Nonsteroidal anti-inflammatories
  • Mechanism of Action Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Wounds

Most Recent Events

  • 07 Jan 2004 No development reported - Preclinical for Wounds in Japan (Topical)
  • 19 Feb 2001 New profile
  • 19 Feb 2001 Preclinical development for Wounds in Japan (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top